MTE
Developed for Presented by Chris Colella David Weinroth Date September 17, 2013 HCP Solutions for Superior Results Brought to you by the leaders in desktop.
NSS Update 2012 Leighton Wilksch Executive Officer, Northern Sustainable Soils Inc.
PAG 2015 - Overview of the Breeding Management System - Dr Graham McLaren
Clinical Trial Design, Biostatistics, Ethics, and Recruitment Clinical Trial Design Anthony J. Murgo, MD.,MS; NCI/DCTD Biostatistics Larry Rubinstein,
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
Meeting Agenda Presentations on endpoints –Regulatory issues –Scientific issues Pros and cons of end points –Classical end points –Non-classical end points.
Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media Colin D. Marchant, M.D. Boston University School of Medicine and Tufts University.
European Parliament Advanced Therapies Hearing May 11, 2006 Advanced Therapies The proposed EU regulation from the viewpoint of a Pharmaceutical company.
TARGET VS INTENSITY: UNDERSTANDING THE NEW ACC/AHA LIPID GUIDELINES Pamela L. Stamm, PharmD, CDE, BCPS, BCACP Associate Professor, Auburn University Harrison.
Evaluating Safety in Analgesic Clinical Trials ─ Including Prospective Capture of Adverse Events IMMPACT XIV: June 17, 2011 Vibeke Strand, MD Clinical.
Estimands at ICH. Rob Hemmings, Statistics and PK Unit manager, MHRA CHMP member, SAWP chair, BSWP / MSWG member.
